GW Pharmaceuticals said early Thursday that the Food and Drug Administration will review a new drug application for its cannabis-derived drug epidiolex for seizures associated with two rare types of childhood epilepsy.
The application was accepted for priority review, a special status that offers an accelerated review for high-priority products, and the regulator aims to have a decision by or on June 27, 2018. If approved, epidiolex -- which contains cannabidiol (CBD), rather than the psychoactive component of cannabis, THC -- could be the country's first cannabis-derived drug.
